Information Provided By:
Fly News Breaks for January 13, 2017
CLVS
Jan 13, 2017 | 08:05 EDT
Morgan Stanley analyst Andrew Berens initiated Clovis with an Overweight and a $68 price target. The analyst expects Clovis' Rubraca to remain a key drug as a third-line agent for treatment of ovarian cancer and should benefit from sequential PARP usage data expected over the next 12-18 months, as well as being an option for patients that do not maintain platinum sensitivity or qualify maintenance intervention.
News For CLVS From the Last 2 Days
There are no results for your query CLVS